Investigational Drug Information for TAK-279
✉ Email this page to a colleague
What is the development status for investigational drug TAK-279?
TAK-279 is an investigational drug.
There have been 6 clinical trials for TAK-279.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 6th 2023.
The most common disease conditions in clinical trials are Psoriasis, Renal Insufficiency, and Liver Diseases. The leading clinical trial sponsors are Takeda, Teva takeda, and [disabled in preview].
There are four US patents protecting this investigational drug and sixteen international patents.
Summary for TAK-279
| US Patents | 4 |
| International Patents | 16 |
| US Patent Applications | 8 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2023-11-06) |
| Vendors | 16 |
Recent Clinical Trials for TAK-279
| Title | Sponsor | Phase |
|---|---|---|
| A Study of TAK-279 in Healthy Chinese Adults | Teva takeda | Phase 1 |
| A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment | Takeda | Phase 3 |
| A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period | Takeda | Phase 3 |
Clinical Trial Summary for TAK-279
Top disease conditions for TAK-279
Top clinical trial sponsors for TAK-279
US Patents for TAK-279
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TAK-279 | ⤷ Sign Up | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (Cambridge, MA) | ⤷ Sign Up |
| TAK-279 | ⤷ Sign Up | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (Cambridge, MA) | ⤷ Sign Up |
| TAK-279 | ⤷ Sign Up | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TAK-279
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TAK-279 | Argentina | AR112287 | 2037-07-28 | ⤷ Sign Up |
| TAK-279 | Australia | AU2018306444 | 2037-07-28 | ⤷ Sign Up |
| TAK-279 | Australia | AU2022279375 | 2037-07-28 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
